Aclaris Therapeutics, Inc. - Common Stock — Filings & Documents (NASDAQ:ACRS) — Page 4 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2024

Current report, Q3 FY2024

Aclaris Therapeutics, Inc. current report, Q3 FY2024

Quarterly report, Q2 FY2024

Aclaris Therapeutics, Inc. quarterly report, Q2 FY2024

1
2
3
4

News

Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Omn

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow (NASDAQ:ACRS) 2026-04-28

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates